Position of the Transparency Council – Kuvan (sapropterin)

At its meeting on 5 August 2024, the Transparency Council adopted position No. 83/2024 on the appropriateness of issuing approvals for the reimbursement of the drug Kuvan (sapropterinum) for the following indications: atypical form of phenylketonuria – tetrahydrobiopterin (BH4) deficiency, including 6-pyruvyltetrahydrobiopterin synthase (6-PTPS) defect, guanosine triphosphate cyclohydrolase (GTP-CH) deficiency

Publication of the position >>